AIM ImmunoTech to Discuss First Quarter 2023 Financial
OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the...
Source: globenewswire.com
Page 9 - Thomask Equels News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Thomask Equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Thomask Equels Today - Breaking & Trending Today
AIM ImmunoTech Inc.: AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
Company's SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech
Source: finanznachrichten.de
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 -- AIM ImmunoTech Inc. ,... | April 12, 2023
Source: marketscreener.com
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
OCALA, Fla., March 27, 2023 -- AIM ImmunoTech Inc. , an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and... | March 27, 2023
Source: marketscreener.com
AIM ImmunoTech (NYSE:AIM) Trading Down 4.2%
AIM ImmunoTech Inc. (NYSE:AIM – Get Rating) traded down 4.2% on Friday . The company traded as low as $0.41 and last traded at $0.42. 93,307 shares were traded during trading, a decline of 64% from the average session volume of 256,005 shares. The stock had previously closed at $0.44. AIM ImmunoTech Stock Down 4.2 […]
Source: theenterpriseleader.com